文献类型：期刊文献

英文题名：Inhalable Mucus-Penetrating Engineered Hybrid Nanomedicine for Enhanced Treatment of Idiopathic Pulmonary Fibrosis

作者：Zou, Jinglin[1];Jiang, Cong[2];Zhang, Jing[2];Wan, Shiyue[2];Yang, Yuzi[1];Leng, Yuheng[1];Wang, Shuqi[1];Jia, Xinlin[3];Mao, Yuanqing[3];Zhang, Dapeng[1];Li, Yongsheng[1]

机构：[1]East China Univ Sci & Technol, Frontier Sci Ctr Mat Biol & Dynam Chem, Shanghai Engn Res Ctr Hierarch Nanomat, Sch Mat Sci & Engn,Lab Low Dimens Mat Chem,Key Lab, Shanghai 200237, Peoples R China;[2]Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Thorac Surg, Shanghai 200092, Peoples R China;[3]Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants,Dept Orthopaed, Shanghai 200011, Peoples R China

年份：2025

卷号：25

期号：31

起止页码：11929

外文期刊名：NANO LETTERS

收录：;EI(收录号：20252918792769);WOS:【SCI-EXPANDED(收录号:WOS:001528633500001)】；

基金：This work was financially supported by the National Key Research and Development Program of China (No. 2022YFC2403200), the National Natural Science Foundation of China (No. 22305081), Leading Talents in Shanghai in 2018, and Shanghai Sailing Program (23YF1408600)

语种：英文

外文关键词：hybrid nanoparticle; pulmonary drug delivery; inhalable nanomedicine; idiopathic pulmonary fibrosis; mucus penetration

摘要：Idiopathic pulmonary fibrosis (IPF) is a life-threatening interstitial lung disease and is one of the complications observed in individuals following COVID-19 infection. Although inhalable nanomedicines hold promise, nebulization-induced shear stress, dense airway mucus barrier, and inefficient in vivo clearance substantially compromise nanomedicine delivery efficiency and biosafety, thereby limiting their therapeutic efficacies. Herein, an inhalable microenvironment-responsive hybrid nanomedicine (PFD@FPNs-CAT) encapsulated with pirfenidone (PFD) and modified with catalase (CAT) is developed, which is able to overcome the supramolecular interactions owing to the small particle size, electronegativity, and PEGylated surface, thus enhancing the accumulation of PFD@FPNs-CAT in the lesions. Moreover, the surface-anchored CAT is demonstrated to relieve hypoxia, thus reversing the immunosuppressive microenvironment and further enhancing the therapeutic efficacy against IPF. Notably, due to the relatively low quantity of silica doping, PFD@FPNs-CAT demonstrates high stability and excellent biocompatibility. This inhalable mucus-penetrating nanomedicine remarkably inhibits the progression of IPF, illuminating the bright prospects for IPF therapy.